Judith Huerta‐Guzmán

933 total citations
42 papers, 666 citations indexed

About

Judith Huerta‐Guzmán is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Judith Huerta‐Guzmán has authored 42 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 25 papers in Oncology and 17 papers in Neurology. Recurrent topics in Judith Huerta‐Guzmán's work include Lymphoma Diagnosis and Treatment (35 papers), CNS Lymphoma Diagnosis and Treatment (17 papers) and Viral-associated cancers and disorders (17 papers). Judith Huerta‐Guzmán is often cited by papers focused on Lymphoma Diagnosis and Treatment (35 papers), CNS Lymphoma Diagnosis and Treatment (17 papers) and Viral-associated cancers and disorders (17 papers). Judith Huerta‐Guzmán collaborates with scholars based in Mexico, Vietnam and United States. Judith Huerta‐Guzmán's co-authors include Agustín Avilés, Natividad Neri, M. Jesús Nambo, Sergio Cleto, Claudia Castañeda, Alejandra Talavera, Serafín Delgado, José C. Díaz‐Maqueo, Agustin Avilés and Margarita L. Contreras and has published in prestigious journals such as Stem Cells and Development, Journal of Surgical Oncology and Oncology.

In The Last Decade

Judith Huerta‐Guzmán

41 papers receiving 650 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Judith Huerta‐Guzmán Mexico 17 400 400 133 116 97 42 666
M. Jesús Nambo Mexico 17 544 1.4× 451 1.1× 90 0.7× 219 1.9× 119 1.2× 42 896
Catherine Traullé France 12 354 0.9× 227 0.6× 150 1.1× 87 0.8× 184 1.9× 20 588
Gregory Bociek United States 14 562 1.4× 379 0.9× 129 1.0× 131 1.1× 230 2.4× 35 836
Maricer P. Escalón United States 12 408 1.0× 263 0.7× 200 1.5× 81 0.7× 117 1.2× 22 724
Alessia Bari Italy 19 550 1.4× 449 1.1× 179 1.3× 147 1.3× 179 1.8× 53 911
José C. Díaz‐Maqueo Mexico 12 261 0.7× 294 0.7× 98 0.7× 89 0.8× 72 0.7× 34 529
Delia Rota Scalabrini Italy 11 447 1.1× 290 0.7× 84 0.6× 188 1.6× 97 1.0× 25 600
Igor Aurer Croatia 20 531 1.3× 449 1.1× 170 1.3× 159 1.4× 223 2.3× 88 950
Liliana Calabrese Italy 11 364 0.9× 184 0.5× 56 0.4× 100 0.9× 180 1.9× 29 743
Paolo Gavarotti Italy 17 501 1.3× 315 0.8× 251 1.9× 208 1.8× 130 1.3× 36 829

Countries citing papers authored by Judith Huerta‐Guzmán

Since Specialization
Citations

This map shows the geographic impact of Judith Huerta‐Guzmán's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Huerta‐Guzmán with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Huerta‐Guzmán more than expected).

Fields of papers citing papers by Judith Huerta‐Guzmán

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Huerta‐Guzmán. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Huerta‐Guzmán. The network helps show where Judith Huerta‐Guzmán may publish in the future.

Co-authorship network of co-authors of Judith Huerta‐Guzmán

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Huerta‐Guzmán. A scholar is included among the top collaborators of Judith Huerta‐Guzmán based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Huerta‐Guzmán. Judith Huerta‐Guzmán is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Avilés, Agustín, et al.. (2013). Combined therapy in untreated patients improves outcome in Nasal NK/T lymphoma: results of a clinical trial. Medical Oncology. 30(3). 637–637. 22 indexed citations
3.
Avilés, Agustín, et al.. (2010). ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 10(2). 125–128. 21 indexed citations
4.
Avilés, Agustín, et al.. (2009). Rituximab and Chemotherapy in Primary Gastric Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 24(1). 25–28. 25 indexed citations
5.
Avilés, Agustín, M. Jesús Nambo, Sergio Cleto, Natividad Neri, & Judith Huerta‐Guzmán. (2009). Rituximab and Dose-Dense Chemotherapy in Primary Testicular Lymphoma. Clinical Lymphoma & Myeloma. 9(5). 386–389. 22 indexed citations
6.
Avilés, Agustín, M. Jesús Nambo, Natividad Neri, et al.. (2007). Interferon and Low Dose Methotrexate Improve Outcome in Refractory Mycosis Fungoides/Sézary Syndrome. Cancer Biotherapy and Radiopharmaceuticals. 22(6). 836–840. 31 indexed citations
7.
Avilés, Agustín, M. Jesús Nambo, Claudia Castañeda, et al.. (2007). Rituximab and Escalated Chemotherapy in Elderly Patients with Aggressive Diffuse Large-Cell Lymphoma: A Controlled Clinical Trial. Cancer Biotherapy and Radiopharmaceuticals. 22(2). 194–199. 15 indexed citations
8.
Avilés, Agustín, M. Jesús Nambo, Natividad Neri, et al.. (2007). Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. Medical Oncology. 24(1). 85–89. 16 indexed citations
9.
Avilés, Agustín, M. Jesús Nambo, Natividad Neri, et al.. (2007). Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Medical Oncology. 24(2). 227–230. 91 indexed citations
10.
Avilés, Agustín, Natividad Neri, M. Jesús Nambo, Judith Huerta‐Guzmán, & Sergio Cleto. (2006). Surgery and Chemotherapy versus Chemotherapy as Treatment of High-Grade MALT Gastric Lymphoma. Medical Oncology. 23(2). 295–300. 11 indexed citations
11.
Avilés, Agustín, Natividad Neri, M. Jesús Nambo, et al.. (2005). Novel therapy in multiple myeloma. Investigational New Drugs. 23(5). 411–415. 5 indexed citations
12.
Avilés, Agustín, et al.. (2004). Gemcitabine and Cisplatin in Refractory Malignant Lymphoma. Oncology. 66(3). 197–200. 16 indexed citations
13.
Avilés, Agustín, Natividad Neri, M. Jesús Nambo, et al.. (2004). Maintenance Therapy with Interferon-α 2b, Cyclophosphamide, and Prednisone in Aggressive Diffuse Large Cell Lymphoma. Stem Cells and Development. 13(2). 205–209. 2 indexed citations
14.
Avilés, Agustín, Sergio Cleto, Natividad Neri, et al.. (2003). Treatment of Advanced Hodgkin's Disease: EBVD versus Intensive Brief Chemotherapy. Leukemia & lymphoma. 44(8). 1361–1365. 2 indexed citations
15.
Avilés, Agustín, et al.. (2003). No Association Between Lymphoma and Hepatitis C Virus. Medical Oncology. 20(2). 165–168. 7 indexed citations
16.
Avilés, Agustín, et al.. (2003). Nasal NK/T-Cell Lymphoma with Disseminated Disease Treated with Aggressive Combined Therapy. Medical Oncology. 20(1). 13–18. 29 indexed citations
17.
Avilés, Agustín, José C. Díaz‐Maqueo, Edna L. García, et al.. (2001). Late Lethal Events in Patients with Diffuse Large B Cell Lymphoma: a Review of 714 Patients Treated in a Single Centre. Leukemia & lymphoma. 42(4). 631–637. 6 indexed citations
18.
Avilés, Agustin, Rodolfo Alejandro, Judith Huerta‐Guzmán, Alejandra Talavera, & Sergio Cleto. (1999). Dexamethasone, All Trans Retinoic Acid and Interferon Alpha 2a in Patients with Refractory Multiple Myeloma. Cancer Biotherapy and Radiopharmaceuticals. 14(1). 23–26. 4 indexed citations
19.
20.
Avilés, Agustín, et al.. (1996). Marginal Zone B cell lymphoma of the parotid glands: Results of a randomised trial comparing radiotherapy to combined therapy. European Journal of Cancer Part B Oral Oncology. 32(6). 420–422. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Jesús Nambo Breakdown of academic impact, for papers by Catherine Traullé Breakdown of academic impact, for papers by Gregory Bociek Breakdown of academic impact, for papers by Maricer P. Escalón Breakdown of academic impact, for papers by Alessia Bari Breakdown of academic impact, for papers by José C. Díaz‐Maqueo Breakdown of academic impact, for papers by Delia Rota Scalabrini Breakdown of academic impact, for papers by Igor Aurer Breakdown of academic impact, for papers by Liliana Calabrese Breakdown of academic impact, for papers by Paolo Gavarotti
Rankless by CCL
2026